To evaluate the effect of neostigmine on blood glucose levels in euglycemic albino rats through OGTT

Suresha R. N., Siddamma Amoghimath, Jayanthi M. K.


Background: Diabetes mellitus (DM) consists of a group of syndromes characterised by hyperglycaemia, altered metabolism of lipids, carbohydrates and proteins and an increased risk of complications from vascular disease. There are genetic and environmental components that affect the risk of developing either type 1 or type 2 diabetes mellitus.

Methods: Twelve Swiss albino rats weighing around 150-200gmsof either sex were randomly selected from the central animal facility, JSSMC, Mysore and divided into two groups. The control group received distilled water (25ml/kg body wt.) per orally, test group received Neostigmine (0.5mg/kg/day) per orally for 5 days. On the fifth day, following overnight fasting, 1 hour after drug administration in all the group of rats OGTT was performed, by administering oral glucose in dose of 0.6gm/kg body weight. The capillary blood glucose level was measured at 0, 60 and 150 minutes, by rat tail snipping method using (ACCUCHEK) glucometer.

Results: The Capillary Blood Glucose levels of Neostigmine group was less when compared to control group at all-time intervals.

Conclusions: Neostigmine showed the hypoglycemic activity when given for 5 days orally in euglycemic albino rats through OGTT.


Capillary blood glucose, Diabetes, Euglycemic, Neostigmine, Oral glucose tolerance test

Full Text:



Abbruzzese JL, Aboulhosn J, Achermann JC, Powers AC, James P. Diabetes mellitus. In Dan L. Longo, Dennis L. Kasper, editors. Harrison’s princples of internal medicine. New York: Mcgraw- hill; 2013:2276-2279.

Nicholson G, Hall GM. Diabetes mellitus: new drugs for a new epidemic. British Journal of Anaesthesia. 2011;107(1):65-73.

Braun M, Ramracheya R, Bengtsson M. Voltage-Gated Ion Channels in Human Pancreatic β Cells: Electrophysiological Characterization and Role in Insulin Secretion. Oxford Centre for Diabetes Endocrinology and Metabolism. Diabetes. 2008;57:1622-7.

Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose Tolerance Test minimal Model Indexes of β-cell Function and Insulin Sensitivity. Diabetes. 2001;50:150-8.

Hilal-Dandan R. Muscarinic receptor agonist and antagonist. In: Bruton LL, editor. Goodman and Gilman’s the Pharmacological Basis of Therapeutics. 12th Ed. China: McGraw Hill; 2011:311-25.

Gautam D, Han SJ, Duttaroy A, Mears D, Hamdan FF, Li JH, et al. Role of the M3 muscarinic acetylcholine receptor in β‐cell function and glucose homeostasis. Diabetes, Obesity and Metabolism. 2007 Nov 1;9(s2):158-69.

Billups D, Billups B, Challiss RJ, Nahorski SR. Modulation of Gq-protein-coupled inositol trisphosphate and Ca2+ signaling by the membrane potential. Journal of Neuroscience. 2006 Sep 27;26(39):9983-95.

Tripathi KD. Cholinergic system and drugs. In: KD Tripathi. Essentials of medical pharmacology. New Delhi: Jaypee; 2013:105-112.

Medhi B, Prakash A. Introduction to experimental pharmacology. In: Bikash Medhi, editors. Practical manual of experimental and clinical pharmacology. New Delhi: Jaypee; 2010:.23-25.

Tuomilehto J. Point: a glucose tolerance test is important for clinical practice. Diabetes Care. 2002;25:1880-2.

Jean-Claude H. Triggering and Amplifying Pathways of Regulation of Insulin Secretion by Glucose. Diabetes. 2000 November 49:1751-60.

Komatsu M, Sato Y, Yamada S, Yamauchi K, Hashizume K, Aizawa T. Triggering of insulin release by a combination of cAMP signal and nutrients. Diabetes. 2002 Feb 1;51(1):S29-32.

Meier JJ, Menge BA, Breuer TGK, Mu¨ller CA, Tannapfel A, Uhl W. Functional Assessment of Pancreatic Cell Area in Humans. Diabetes. 2009 July 58:1595-603.